Results 51 to 60 of about 3,441 (189)

Cyclic Peptide Conformational Landscapes Through the Lens of Mass Spectrometry and Orthogonal Spectroscopy

Journal of Mass Spectrometry, Volume 61, Issue 5, May 2026.
ABSTRACT Cyclic peptides occupy a structurally dynamic region of chemical space, where function often arises from ensembles rather than a single dominant fold. Closed backbones, frequent N‐methylation, heteroatoms, unnatural amino acids, and a strong propensity for metal coordination create dense conformational and coordination landscapes that ...
Emmanuel Nkyaagye, Happy Abena Safoah, Thanh D. Do   +2 more
wiley   +1 more source

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. [PDF]

PLoS ONE, 2012
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity.
Huihui Chong, Xue Yao, Chao Zhang, Lifeng Cai, Sheng Cui, Youchun Wang, Yuxian He   +6 more
doaj   +1 more source

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile

Pharmaceuticals, 2022
Recently, a series of highly effective peptide- or protein-based HIV fusion inhibitors have been identified. However, due to their short half-life, their clinical application is limited.
Wei Xu, Zhe Cong, Qianyu Duan, Qian Wang, Shan Su, Rui Wang, Lu Lu, Jing Xue, Shibo Jiang   +8 more
doaj   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia [PDF]

, 2003
The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the ...
Salgo, Miklos, Lazzarin, A., Lange, J.M.A., Clotet, Bonaventura, Katlama, Christine, Salgo, M., Lange, Joep, Wat, Cynthia, Delfraissy, JF, DeMasi, R, Neslon, M, Clotet, B., Clotet, B, Lazzarin, Adriano, Lazzarin, A, Katlama, C, Stellbrink, H.J., Nelson, M., Wat, C., Delfraissy, J.F., Drobnes, C., Huson, L., Katlama, C., Cooper, David, Nelson, Mark, Delehanty, John, Wat, C, Reynes, J., Cooper, D., Delehanty, J., Reynes, J, Drobnes, C, Saldo, M, TORO-2 study group, -, DeMasi, Ralph, Ende, Marchina, Reynes, Jacques, Arastéh, Keikawus, Stellbrink, HJ, Drobnes, Claude, Stellbrink, Hans-Jürgen, Huson, L, Arasteh, K, De Masi, R., Cooper, D, Delehanty, J, Huson, Les, Lange, J, Arasteh, K., Delfraissy, Jean-François   +49 more
core   +1 more source

Valproic acid and HIV-1 latency: beyond the sound bite

Retrovirology, 2005
A recent publication in Lancet by Dr. David Margolis and colleagues raised the prospect that HIV infection may be curable. In this pilot study, which received much attention from the press, Dr.
Smith Stephen M
doaj   +1 more source

Multifactorial Perspective for Greening Solid‐Phase Peptide Synthesis: Rigid Polyacrylate Macroporous Resin in Combination with Green Solvents

ChemSusChem, Volume 19, Issue 7, 14 April 2026.
A rigid, non‐swelling polyacrylate resin enables greener solid‐phase peptide synthesis by allowing various green solvents during the peptide synthesis and significantly reduced process mass intensity without compromising peptide synthesis efficiency/purity.
Sikabwe Noki, Ashish Kumar, Cheng Zhang, Alesandra Basso, Simona Serban, Xiaokang Kou, Yanjun Li, Anamika Sharma, Beatriz G. de la Torre, Fernando Albericio   +9 more
wiley   +1 more source

Virological fitness of HIV in patients with resistance to enfuvirtide [PDF]

, 2007
Resistance to the HIV fusion inhibitor enfuvirtide is associated with mutations in the first heptad repeat region of gp41, but little is known of their impact on replicative fitness in vivo.
Megan Gooey (20012388), Vanessa Roulet (20012382), Jodie Nicholls (20012391), Chris Birch (20128), Louise Carolan (14686636), Anastasia Papadakis (20012394), Doris Chibo (503921), Katharina Skrabal (20012385), Norman Roth (300177)   +8 more
core  

Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitorMechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor [PDF]

, 2008
We present a model of the pharmacokinetics of enfuvirtide, a potent inhibitor of the fusion of human immunodeficiency virus type 1 (HIV-1) with target cells.
Mohanty, Utkala, Dixit, Narendra M
core  

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.

PLoS Pathogens, 2019
The clinical application of conventional peptide drugs, such as the HIV-1 fusion inhibitor enfuvirtide, is limited by their short half-life in vivo. To overcome this limitation, we developed a new strategy to extend the in vivo half-life of a short HIV-1
Wenwen Bi, Wei Xu, Liang Cheng, Jing Xue, Qian Wang, Fei Yu, Shuai Xia, Qi Wang, Guangming Li, Chuan Qin, Lu Lu, Lishan Su, Shibo Jiang   +12 more
doaj   +1 more source